两种化疗方案联合地西他滨治疗骨髓异常增生综合征继发AML临床对比研究.docVIP

两种化疗方案治疗高龄高龄骨髓异常增生综合征继发AML临床对比研究 【摘要】目的: 探讨临床疗效及安全性。方法：研究对象选取我院20年月-201年月收治患者共0例，以随机区组法分为A组B组，，比较两组患者临床疗效，及发生率等。结果：组患者临床差异统计学意义（p0.05）；组患者显著于A组，差异有统计学意义（p 0.05）（p0.05）结论：。 【关键词】Clinical comparative study of two kinds of chemotherapy regimen in the treatment of elderly patients with AML transformed by abnormal proliferation of bone marrow Abstract：Objective To investigate the clinical effect and safety differences of 3+7 and Decitabine + HAG pre-excitation regimen in the treatment of elderly patients with AML transformed by abnormal proliferation of bone marrow. Methods 50 elderly patients with AML transformed by abnormal proliferation of bone marrow were chosen in the period from March 2012 to May 2014 and randomly divided into 2 groups including A group 25 elderly patients with 3+7 regimen and B group 25 elderly patients with Decitabine + HAG pre-excitation regimen; and the clinical effects, the median survival time and the incidence of drug adverse effects of 2 groups were compared. Results The clinical total remission rate of B group was significantly better than A group（p 0.05）. The median survival time of group was significantly longer than A group（p 0.05）. Theincidence of drug adverse effects between 2 groups（p0.05）. Conclusion 3+7 regimen, Decitabine + HAG pre-excitation regimen in the treatment of elderly patients with AML transformed by abnormal proliferation of bone marrow can efficiently delay the disease progression process, prolong the survival time and not increase the drug adverse effects risk.? [Key Words] Decitabine; pre-excitation; abnormal proliferation of bone marrow; AML AML属于造血系统常见恶性克隆性疾病类型之一，尽管随着现代医学治疗手段发展，患者肿瘤缓解效果及远期生存时间均显著改善，但针对老年人群尚无特别有效方案。老年AML患者因受年龄、身体机能状态、合并基础疾病及原发病为骨髓增生异常综合征等因素制约，无法采用大剂量化疗药物及后续骨髓移植方案[1]；而传统“3+7”化疗方案应用与低年龄相比疗效欠佳，中位生存时间多不足2个月，无法满足临床需要。近年来国内外研究显示，地西他滨用于老年AML患者临床治疗缓解效果良好[2-3]，但对于骨髓异常增生综合征继发者是否可获得相似疗效尚无明确定论。本次研究我院20年月-201年月收治患者共0例，，比较两组患者临床疗效，及发生率等，探讨临床疗效及安全性。 资料与方法 临床资料 研究对象选取我院20年月-201年月收治患者共0例，以随机区组法分为A组B组每组各例A组患者中男性